Are patients with phyllodes tumor of the breast good candidates for breast conserving therapy? A single center experience

Introduction: Phyllodes tumor of the breast (PTB) constitutes 0.2-2% of all breast tumors. The optimal extent of surgical excision (breast conserving surgery or mastectomy) is a matter of debate, especially for cases of borderline and malignant PTBs. From 1995 breast conserving surgery (BCS) is the treatment of choice in all patients with PTB in Cancer Center and Institute of Oncology in Krakow. The purpose of this study is to present experience with BCT patients with PTB at a single institution in Poland. Materials and Methods: Between January 1995 and December 2011, 101 women with PTB were primarily treated surgically at this center. Of these 101 patients, 87 (86.1%) underwent BCS and in 14 (13.9%) patients the mastectomy was performed. This study focused on a group of 87 patients treated with BCS. In 87 patients resection margins were negative. In 82 patients (94.3%) the surgical margin width ranged between 1-2 cm, but in five (5.7%) cases (three malignant and two borderline) it was less than 1 cm (range 0.2-0.9 mm). Those five patients were postoperatively irradiated. Results: In all 87 patients with PTB who were treated with BCS, 83 (95.4%) patients survived five years with no evidence of disease. Two patients (one benign PTB and one borderline PTB) died due to myocardial infarction. In the presented group during five-year follow-up, only two (2.3%) patients died because of malignant PTB (with lung metastases). None of patients developed a local recurrence. Conclusion: The treatment of choice for patients with PTB is BCS. If surgical margin is < 1 cm, adjuvant radiotherapy should be considered.

Phyllodes tumor; Breast conserving surgery (BCS); Breast conserving therapy (BCT).

[1] Spitaleri G., Toesca A., Botteri E., Bottiglieri L., Rotmensz N., Boselli S., et al.: “Breast phyllodes tumor: a review of literature and a single center retrospective series analysis”. Crit. Rev. Oncol. Hematol ., 2013, 88, 427.

[2] Khosravi-Shahi P.: “Management of non metastatic phyllodes tumors of the breast: review of the literature”. Surg. Oncol., 2011, 20, e143.

[3] Barth R.J. Jr., Wells W.A., Mitchell S.E., Cole B.F.: “A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors”. Ann. Surg. Oncol., 2009, 16, 2288.

[4] Belkacemi Y., Bousquet G., Marsiglia H., Ray-Coquard I., Magne N., Malard Y., et al.: “Phyllodes tumor of the breast”. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70, 492.

[5] Borhani-Khomani K., Talman M.L., Kroman N., Tvedskov T.F.: “Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study”. Ann. Surg. Oncol., 2016, 23, 1543.

[6] Tse G.M., Niu Y., Shi H.J.: “Phyllodes tumor of the breast: an update”. Breast Cancer, 2010, 17, 29.

[7] Mitus J.W., Blecharz P., Reinfuss M., Kulpa J.K., Skotnicki P., Wysocki W.M.: “Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience”. Med. Sci. Monit., 2013, 19, 1183.

[8] Kim S., Kim J.Y., Kim D.H., Jung W.H., Koo J.S.: “Analysis of phyllodes tumor recurrence according to the histologic grade”. Breast Cancer Res. Treat., 2013, 141, 353.

[9] Lakhani S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J.: “WHO classification of tumours of the breast”. 4thed. IARC”. Lyon: 2012, 142.

[10] Telli M.L., Horst K.C., Guardino A.E., Dirbas F.M., Carlson R.W.: “Phyllodes tumors of the breast: natural history, diagnosis, and treatment”. J. Natl. Compr. Canc. Netw., 2007, 5, 324.

[11] Pezner R.D., Schultheiss T.E., Paz I.B.: “Malignant phyllodes tumor of the breast: local control rates with surgery alone”. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 710.

[12] Ben Hassouna J., Damak T., Gamoudi A., Chargui R., Khomsi F., Mahjoub S., et al.: “Phyllodes tumors of the breast: a case series of 106 patients”. Am. J. Surg., 2006, 192, 141.

[13] Barrio A.V., Clark B.D., Goldberg J.I., Hoque L.W., Bernik S.F., Flynn L.W., et al.: “Clinicopathologic features and long-term out comes of 293 phyllodes tumors of the breast”. Ann. Surg. Oncol., 2007, 14, 2961.

[14] Kapiris I., Nasiri N., A’Hern R., Healy V., Gui G.P.: “Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast”. Eur. J. Surg. Oncol., 2001, 27, 723.

[15] Chen W.H., Cheng S.P., Tzen C.Y., Yang T.L., Jeng K.S., Liu C.L., et al.: “Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases”. J. Surg. Oncol., 2005, 91, 185.

[16] Guillot E., Couturaud B., Reyal F., Curnier A., Ravinet J., Lae M., et al.: “Management of phyllodes breast tumors”. Breast J., 2011, 17, 129.

[17] Cheng S.P., Chang Y.C., Liu T.P., Lee J.J., Tzen C.Y., Liu C.L.: “Phyllodes tumor of the breast: the challenge persists”. World J. Surg., 2006, 30, 1414.

[18] Acar T., Tarcan E., Haciyanli M., Kamer E., Peskersoy M., Yigit S., et al.: “How to approach phyllodes tumors of the breast?”. Ulus. Cerrahi. Derg., 2015, 31, 197.

[19] Jang J.H., Choi M.Y., Lee S.K., Kim S., Kim J., Lee J., et al.: “Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast”. Ann. Surg. Oncol., 2012, 19, 2612.

[20] Teo J.Y., Cheong C.S., Wong C.Y.: “Low local recurrence rates in young Asian patients with phyllodes tumours: less is more”. ANZ. J. Surg., 2012, 82, 325.

[21] Yom C.K., Han W., Kim S.W., Park S.Y., Park I.A., Noh D.Y.: “Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast”. Ann. Surg. Oncol., 2015, 22, 2912.

[22] Tan B.Y., Acs G., Apple S.K., Badve S., Bleiweiss I.J., Brogi E., et al.: “Phyllodes tumours of the breast: a consensus review”. Histopathology, 2016, 68, 5.

[23] Lin C.C., Chang H.W., Lin C.Y., Chiu C.F., Yeh S.P.: “The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan”. Int. J. Clin. Oncol., 2013, 18, 614.

[24] Haberer S., Lae M., Seegers V., Pierga J.Y., Salmon R., Kirova Y.M., et al.: “Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie”. Cancer Radiother., 2009, 13, 305.

[25] Onkendi E.O., Jimenez R.E., Spears G.M., Harmsen W.S., Ballman K.V., Hieken T.J.: “Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome”. Ann. Surg. Oncol., 2014, 21, 3304.

[26] Bouhafa T., Masbah O., Bekkouch I., Afqir S., Mellas N., Ismaili N., et al.: “Phyllodes tumors of the breast: analysis of 53 patients”. Cancer Radiother. 2009;13(2):85-91. doi: 10.1016/j.canrad.2008.11.007.

[27] Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. “Primary treatment of cystosarcoma phyllodes of the breast”. Cancer. 2000;89(7):1502-11.

[28] Mitus J., Reinfuss M., Mitus J.W., Jakubowicz J., Blecharz P., Wysocki W.M., et al.: “Malignant phyllodes tumor of the breast: treatment and prognosis”. Breast J., 2014, 20, 639.

[29] Carlson R.W., Larsen J.K., McClure J., Fitzgerald C.L., Venook A.P., Benson A.B. 3rd., et al.: “International adaptations of NCCN Clinical Practice Guidelines in Oncology”. J. Natl. Compr. Canc. Netw., 2016, 2, 2016.

[30] Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al.: “Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples”. Br. J. Cancer, 1977, 35, 1.

[31] Pimiento J.M., Gadgil P.V., Santillan A.A., Lee M.C., Esposito N.N., Kiluk J.V., et al.: “Phyllodes tumors: race-related differences”. J. Am. Coll. Surg., 2011, 213, 537.

[32] Tan P.H., Thike A.A., Tan W.J., Thu M.M., Busmanis I., Li H., et al.: “Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins”. J. Clin. Pathol., 2012, 65, 69.

[33] Ramakant P., Chakravarthy S., Cherian J.A., Abraham D.T., Paul M.J.: “Challenges in management of phyllodes tumors of the breast: a retrospective analysis of 150 patients”. Indian J. Cancer, 2013, 50, 345.

[34] Karim R.Z., Gerega S.K., Yang Y.H., Spillane A., Carmalt H., Scolyer R.A., et al.: “Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution”. Breast, 2009, 18, 165.

[35] Taira N., Takabatake D., Aogi K., Ohsumi S., Takashima S., Nishimura R., et al.: “Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin”. Jpn. J. Clin. Oncol., 2007, 37, 730.

[36] Abdalla H.M., Sakr M.A.: “Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast”. J. Egypt Natl. Canc. Inst., 2006, 18, 125.

[37] Mallick S., Joshi N.P., Roy S., Gandhi A.K., Pandit S., Sharma D., et al.: “Malignant and borderline phyllodes tumor of breast treated with a multi-modality approach in a tertiary cancer care centre in North India”. South Asian J. Cancer, 2016, 5, 1.

[38] Pandey M., Mathew A., Kattoor J., Abraham E.K., Mathew B.S., Rajan B., et al.: “Malignant phyllodes tumor”. Breast J., 2001, 7, 411.

[39] Narayanakar R.P., Gangaiah D.M., Althaf S., Dev K., Kurpad V., Gurawalia J.: “Cystosarcoma phyllodes: Pathological enigma: A retrospective review of 162 cases”. Indian J Cancer, 2015, 52, 365.

[40] Mitus J.W., Blecharz P., Walasek T., Reinfuss M., Jakubowicz J., Kulpa J.: “Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast”. World J. Surg., 2016, 40, 323.

[41] Reinfuss M., Mitus J., Duda K., Stelmach A., Rys J., Smolak K.: “The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases”. Cancer, 1996, 77, 910.

[42] Wang H., Wang X., Wang C.F.: “Comparison of clinical characteristics between benign borderline and malignant phyllodes tumors of the breast”. Asian Pac. J. Cancer Prev., 2014, 15, 10791.

[43] Asoglu O., Ugurlu M.M., Blanchard K., Grant C.S., Reynolds C., Cha S.S., et al.: “Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors”. Ann. Surg. Oncol., 2004, 11, 1011.

[44] Verma S., Singh R.K., Rai A., Pandey C.P., Singh M., Mohan N.: “Extent of surgery in the management of phyllodes tumor of the breast: a retrospective multicenter study from India”. J. Cancer Res. Ther., 2010, 6, 511.

[45] Ossa C.A., Herazo F., Gil M., Echeverri C., Angel G., Borrero M., et al.: “Phyllodes tumor of the breast: a clinic-pathologic study of 77 cases in a Hispanic cohort”. Colomb Med. (Cali), 2015, 46, 104.

[46] Gnerlich J.L., Williams R.T., Yao K., Jaskowiak N., Kulkarni S.A.: “Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009”. Ann. Surg. Oncol., 2014, 21, 1222.